Haemophilus Influenzae Type b Clinical Trial
Official title:
Study in Healthy Children of GSK Biologicals' DTPa-IPV/Hib-MenC-TT Vaccine, GSK2197870A, Co-administered With Prevenar™ as a Three-dose Primary Vaccination Course in Infancy Followed by a Booster Dose of Menitorix™ at 12 Months of Age
Verified date | September 2016 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this Phase II study is to evaluate the feasibility of GSK Biologicals' GSK2197870A vaccine co-administered with Wyeth-Lederle's Prevenar™ when given in healthy infants as a three-dose primary vaccination course at 2, 3 and 4 months of age followed by a booster dose of GSK Biologicals' Menitorix™ at 12 months of age.
Status | Completed |
Enrollment | 284 |
Est. completion date | December 9, 2010 |
Est. primary completion date | March 31, 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Weeks to 12 Weeks |
Eligibility |
Inclusion Criteria: All subjects must satisfy the following criteria at study entry: - A male or female infant between, and including, 6 and 12 weeks of age at the time of the first vaccination. - Born after 36 to 42 weeks of gestation. - Subjects who the investigator believes that their parents/ guardians can and will comply with the requirements of the protocol should be enrolled in the study. - Written informed consent obtained from the parent or guardian of the subject. - Healthy subjects as established by medical history and clinical examination before entering into the study. Exclusion Criteria: The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study: - Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. - Chronic administration of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed. - Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. - Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period. - Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product . - Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis, Hib, pneumococcal and/or group C meningococcal vaccination or disease. - History of seizures or progressive neurological disease (one episode of febrile convulsion does not constitute an exclusion criterion). - Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). - History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s). - Major congenital defects or serious chronic illness. The following condition is temporary or self limiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met: • Current febrile illness or axillary temperature =37.5ºC or other moderate to severe illness within 24 hours of study vaccine administration |
Country | Name | City | State |
---|---|---|---|
United Kingdom | GSK Investigational Site | Bristol | |
United Kingdom | GSK Investigational Site | Ely | Cambridgeshire |
United Kingdom | GSK Investigational Site | London | |
United Kingdom | GSK Investigational Site | Oxford | Oxfordshire |
United Kingdom | GSK Investigational Site | Southampton | Hampshire |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United Kingdom,
Khatami A, Snape MD, Ohene-Kena B, Young K, Oeser C, Michaelis LJ, Macleod E, Smee H, Van Der Meeren O, Leyssen M, Caubet M, Yu LM, Heath PT, Faust SN, Finn A, Pollard AJ. Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants. Pediatr Infect Dis J. 2013 Jun;32(6):675-81. doi: 10.1097/INF.0b013e31828672a7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Seroprotected Subjects for Anti-polyribosylribitol Phosphate (Anti-PRP). | A seroprotected subject was defined as a vaccinated subject who had anti-PRP antibody concentrations = 0.15 micrograms per milliliter (µg/mL). | At Month 3 | |
Primary | Number of Seropositive Subjects Against Neisseria Meningitidis Using Baby Rabbit Complement (rSBA-MenC) | A seropositive subject was defined as a vaccinated subject who had rSBA-MenC = 1:8. | At Month 2 and Month 3. | |
Secondary | Number of Subjects With Anti-PRP Concentrations Antibody Above the Cut-off. | The reference cut-off was = 1.0 micrograms per milliliter (µg/mL). | At Month 3 | |
Secondary | Number of Subjects With Anti-polysaccharide C (Anti-PSC ) Antibody Concentrations Above the Cut-offs. | The reference cut-offs were = 0.3 µg/mL and = 2 µg/mL. | At Month 2 and Month 3. | |
Secondary | Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies. | A seroprotected subject was defined as a vaccinated subject who had anti-D and anti-T antibody concentrations = 0.1 international units per milliliter (IU/mL). | At Month 3. | |
Secondary | Number of Seropositive Subjects Against Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN). | A seropositive subject was defined as a vaccinated subject who had anti-PT, anti-FHA and anti-PRN antibody concentrations = 5 enzyme-linked immunosorbent assay (ELISA) units per milliliters (EL.U/mL). | At Month 3. | |
Secondary | Number of Seroprotected Subjects for Anti-poliovirus (Anti-polio) Types 1, 2 and 3. | A seroprotected subject was defined as a vaccinated subject who had anti-polio 1, 2 and 3 antibody concentrations = 1:8. | At Month 3. | |
Secondary | Number of Seropositive Subjects for Anti-pneumococcal (Anti-PNE) Serotypes. | A seropositive subject was defined as a vaccinated subject who had anti- pneumococcal antibody concentrations = 0.2 micrograms per milliliter (µg/mL). The anti-PNE serotypes assessed were 4, 6B, 9V, 14, 18C, 19F and 23F. | At Month 3 | |
Secondary | Concentrations for Anti-PRP. | Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection reference cut-off value was = 0.15 µg/mL. | At Month 3. | |
Secondary | Titers for rSBA-MenC. | Titers were expressed as geometric mean titers (GMCs). The seropositivity reference cut-off value was = 1:8. | At Month 2 and Month 3. | |
Secondary | Concentrations for Anti-PSC. | Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection reference cut-off value was = 0.3 µg/mL. | At Month 2 and Month 3. | |
Secondary | Concentrations for Anti-T and Anti-D. | Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection reference cut-off value was = 0.1 IU/mL. | At Month 3. | |
Secondary | Concentrations for Anti-PT, Anti-FHA and Anti-PRN. | Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity reference cut-off value was = 5 EL.U/mL. | At Month 3. | |
Secondary | Titers for Anti-polio 1, 2 and 3. | Titers were expressed as geometric mean titers (GMTs). The seropositivity reference cut-off value was = 1:8. | At Month 3. | |
Secondary | Concentrations for Anti-PNE Serotypes. | Concentrations were expressed as geometric mean concentreations (GMCs). The seropositivity reference cut-off value was = 0.2 µg/mL. | At Month 3. | |
Secondary | Number of Seroprotected Subjects for Anti-PRP. | A seroprotected subject was defined as a vaccinated subject who had anti-PRP antibody concentrations = 0.15 micrograms per milliliter (µg/mL). | At Month 10 and Month 11. | |
Secondary | Number of Seropositive Subjects Against rSBA-MenC. | A seropositive subject was defined as a vaccinated subject who had rSBA-MenC = 1:8. | At Month 10 and Month 11. | |
Secondary | Number of Subjects With Anti-PSC Antibody Concentrations Above the Cut-offs. | The reference cut-offs were = 0.3 µg/mL and = 2 µg/mL. | At Month 10 and Month 11. | |
Secondary | Number of Seroprotive Subjects for Anti-D and Anti-T Antibodies. | A seropositive subject was defined as a vaccinated subject who had anti-D (ELISA) and anti-T antibody concentrations = 0.1 IU/mL. Seropositivity for anti-D was also defined with the = 0.016 IU/mL cut-off (Neutralisation assay). | At Month 10. | |
Secondary | Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN. | A seropositive subject was defined as a vaccinated subject who had anti-PT, anti-FHA and anti-PRN antibody concentrations = 5 enzyme-linked immunosorbent assay (ELISA) units per milliliters (EL.U/mL). | At Month 10. | |
Secondary | Number of Seroprotected Subjects for Anti-anti-polio Types 1, 2 and 3. | A seroprotected subject was defined as a vaccinated subject who had anti-polio 1, 2 and 3 antibody concentrations = 1:8. | At Month 10. | |
Secondary | Concentrations for Anti-PRP. | Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection reference cut-off value was = 0.15 µg/mL. | At Month 10 and Month 11. | |
Secondary | Titers for rSBA-MenC. | Titers were expressed as geometric mean titers (GMCs). The seropositivity reference cut-off value was = 1:8. | At Month 10 and Month 11. | |
Secondary | Concentrations for Anti-PSC. | Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection reference cut-off value was = 0.3 µg/mL. | At Month 10 and Month 11. | |
Secondary | Concentrations for Anti-T and Anti-D. | Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection reference cut-off value was = 0.1 IU/mL. Seropositivity for anti-D was also defined with the = 0.016 IU/mL cut-off (Neutralisation assay). | At Month 10. | |
Secondary | Concentrations for Anti-PT, Anti-FHA and Anti-PRN. | Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity reference cut-off value was = 5 EL.U/mL. | At Month 10. | |
Secondary | Titers for Anti-polio 1, 2 and 3. | Titers were expressed as geometric mean titers (GMTs). The seroprotection reference cut-off value was = 1:8. | At Month 10. | |
Secondary | Number of Subjects With a Booster Response to rSBA-MenC Antibodies. | Booster response defined as: for initially seronegative subjects, antibody titre = 1:32 at post-booster (Month 11); for initially seropositive subjects, antibody titres at post-booster = 4 fold the pre-booster. | At Month 11 | |
Secondary | Number of Subjects With a Booster Response to Anti-PRP Antibodies. | Booster response defined as: for initially seronegative subjects, antibody concentration = 0.6 µg/mL at post-booster (Month 11); for initially seropositive subjects, antibody concentrations at post-booster = 4 fold the pre-booster. | At Month 11 | |
Secondary | Number of Subjects With a Booster Response to Anti-PSC Antibodies. | Booster response defined as: for initially seronegative subjects, antibody concentration = 1.2 µg/mL at post-booster (Month 11); for initially seropositive subjects, antibody concentrations at post-booster = 4 fold the pre-booster. | At Month 11 | |
Secondary | Number of Subjects Reporting Any Solicited Local Symptoms. | Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade. | During the 8-day (Days 0-7) | |
Secondary | Number of Subjects Reporting Any Solicited General Symptoms. | Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever [axillary temperature above (=) 37.5 degrees Celsius (°C)]. Any = occurrence of any local symptom regardless of intensity grade. | During the 8-day (Days 0-7) | |
Secondary | Number of Subjects Reporting Any Unsolicited Adverse Events (AEs). | An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of an AE regardless of intensity grade or relationship to study vaccination. | Within the 31-day (Days 0-30) follow up period after vaccination. | |
Secondary | Number of Subjects Reporting Any Serious Adverse Events (SAEs). | SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity of a study subjects. Any SAE = any SAE regardless of assessment of relationship to study vaccination. | During the entire study period (Month 0 to Month 11) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Completed |
NCT01214889 -
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
|
Phase 3 | |
Completed |
NCT00534833 -
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
|
Phase 3 | |
Completed |
NCT00379977 -
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age
|
Phase 3 | |
Completed |
NCT00153556 -
Study to Eliminate Hib Carriage in Rural Alaska Native Villages
|
Phase 4 | |
Completed |
NCT02853929 -
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
|
Phase 4 | |
Completed |
NCT02858440 -
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
|
Phase 3 | |
Completed |
NCT01983540 -
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
|
Phase 3 | |
Completed |
NCT01878435 -
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
|
N/A | |
Completed |
NCT00401531 -
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
|
Phase 3 | |
Completed |
NCT00376779 -
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age
|
Phase 2 | |
Completed |
NCT00831311 -
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
|
Phase 2 | |
Completed |
NCT01457547 -
Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course
|
Phase 4 | |
Completed |
NCT00254917 -
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
|
Phase 4 | |
Completed |
NCT01453998 -
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
|
Phase 2 | |
Completed |
NCT01449812 -
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine
|
Phase 3 | |
Completed |
NCT00808392 -
Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b
|
Phase 3 | |
Completed |
NCT00307567 -
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
|
Phase 2 | |
Completed |
NCT00323050 -
Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects
|
Phase 3 | |
Completed |
NCT00325156 -
Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants
|
Phase 4 |